


AMENDMENTS TO THE CLAIMS

1. (Previously Presented) A compound of the formula Z:



where;

A is CH or N;

R₁ is a substituent to a carbon atom in the ring containing A selected from

-S(=O)_pR_a,

where R_a is -C₁-C₄ alkyl, -OR_x, -NR_xR_x, -NHN(R_x)R_x, -NHNHC(=O)OR_x, -NR_xOH;

-C(=O)-R_b,

where R_b is -C₁-C₄-alkyl, OR_x, -NR_xR_x, -NHN(R_x)R_x,

-NHC₁-C₃-alkyl-C(=O)OR_x;

-NR_xR_c,

where R_c is H, C₁-C₄ alkyl, -NR_xR_x; -C(=O)R_d, -CN, S(=O)_pR_x

where R_d is C₁-C₄-alkyl, -OR_x, -NR_xR_x

-C₁-C₃-alkyl-O-C₁-C₃alkylC(=O)OR_x;

-C₁-C₃-alkyl-COOR_x;

-C₁-C₃alkyl-OR_x;

-(O-C₁-C₃alkyl)_q-O-R_x;

a 5 or 6 membered aromatic ring have 1-3 hetero atoms;

p and q are independently selected from 1 or 2;

Rx is independently selected from H, C₁-C₄ alkyl or acetyl; or a pair of Rx can together with the adjacent N atom form a pyrrolidine, piperidine, piperazine or morpholine ring;

R₂ is a substituent to a carbon atom in the ring containing A and is H, halo, cyano, C₁-C₄-alkyl, haloC₁-C₄-alkyl;

L is -O-, -S(=O)_r- or -CH₂-, where r is 0, 1 or 2;

R₃ is H, C₁-C₃ alkyl;

R₄-R₇ are independently selected from H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, haloC₁-C₆ alkyl, C₁-C₆ alkanoyl, haloC₁-C₆ alkanoyl, C₁-C₆ alkoxy, haloC₁-C₆ alkoxy, C₁-C₆ alkyloxyC₁-C₆ alkyl, haloC₁-C₆ alkyloxyC₁-C₆ alkyl, hydroxyC₁-C₆ alkyl, aminoC₁-C₆ alkyl, carboxyC₁-C₆ alkyl, cyanoC₁-C₆ alkyl, amino, carboxy, carbamoyl, cyano, halo, hydroxy, keto;

X is -(CR₈R₈')_n-D-(CR₈R₈')_m;

T is O or S;

D is a bond, -NR₉-, -O-, -S-, -S(=O)- or -S(=O)₂-;

n and m are independently 0, 1 or 2, provided that they are not both 0 when D is a bond;

R₈ and R₈' are independently H, C₁-C₃ alkyl, haloC₁-C₃alkyl, hydroxy, or R₈ and R₈' together with their adjacent C atom is -C(=O)-


R₉ is independently H, C₁-C₃ alkyl;

and pharmaceutically acceptable salts and prodrugs thereof;

with the proviso that R₁ as -C(=O)Rb is not morpholinoketo-.

2. (Original) A compound according to claim 1, wherein T is O.

3. **(Original)** A compound according to claim 1, wherein R₃ is H.
4. **(Previously Presented)** A compound according to claim 1, wherein the cyclopropyl moiety has an enantiomeric excess of the conformation depicted in the partial formulae:




where X is as defined, Y is the bond to the (substituted) phenyl ring depicted in formula I and Z is the bond to the (thio)urea-pyridyl moiety depicted in formula Z.

5. **(Original)** A compound according to claim 1 wherein the compound of formula Z comprises an enantiomeric excess of the isomer showing negative optical activity.
6. **(Original)** A compound according to claim 1, wherein D is -O-
7. **(Original)** A compound according to claim 6, wherein n is 0 and m is 1.
8. **(Original)** A compound according to claim 1, wherein R₄ is hydrogen, fluoro or hydroxy.
9. **(Original)** A compound according to claim 1, wherein R₅ is hydrogen, fluoro, C1-3 alkylcarbonyl or C1-3alkyloxy.
10. **(Original)** A compound according to claim 1, wherein R₆ is hydrogen, halo, C1-C3alkyloxy, C1-3alkylcarbonyl, cyano or ethynyl.

11. **(Original)** A compound according to claim 10, wherein R6 is hydrogen, methoxy or fluoro.
12. **(Original)** A compound according to claim 1, wherein R7 is hydrogen, cyano, halo, C1-3alkyloxy, or C1-3alkylcarbonyl.
13. **(Original)** A compound according to claim 12, wherein R7 is cyano, fluoro or acetyl.
14. **(Original)** A compound according to claim 1, wherein R5 and R6 are H and R4 and R7 are fluoro.
15. **(Original)** A compound according to claim 1, wherein R4 is fluoro, R5 and R6 are H, and R7 is cyano or acetyl.
16. **(Original)** A compound according to claim 1, wherein L is -O-.
17. **(Original)** A compound according to claim 1, wherein R1 is -S(=O)₂NR_xR_x, S(=O)₂C₁-C₄ alkyl, or S(=O)C₁-C₄ alkyl.
18. **(Original)** A compound according to claim 17, wherein R1 is -S(=O)₂NH₂, -S(=O)₂NMe₂ or -S(=O)₂NH-cyclopropyl.
19. **(Original)** A compound according to claim 17, wherein R1 is -S(=O)₂Me or -S(=O)Me.


20. **(Original)** A compound according to claim 1, wherein R1 is $-\text{C}(=\text{O})\text{OR}_x$, $-\text{C}(=\text{O})\text{NR}_x\text{R}_x$, $-\text{C}(=\text{O})\text{NHN}_x\text{R}_x$ or $-\text{C}(=\text{O})\text{NHCH}_2\text{COOR}_x$.
21. **(Original)** A compound according to claim 20, wherein R1 is $-\text{C}(=\text{O})\text{OH}$, $-\text{C}(=\text{O})\text{OMe}$, $-\text{C}(=\text{O})\text{NH}_2$, $-\text{C}(=\text{O})\text{NHMe}$, $-\text{C}(=\text{O})\text{NHNH}_2$, $-\text{C}(=\text{O})\text{NHCH}_2\text{COOH}$.
22. **(Original)** A compound according to claim 20, wherein R1 is $-\text{C}(=\text{O})\text{NR}_x'-\text{N}$ -morpholine, $-\text{C}(=\text{O})\text{NR}_x'-\text{N}$ -piperidine, $-\text{C}(=\text{O})\text{NR}_x'-\text{N}$ -pyrrolidine or $-\text{C}(=\text{O})\text{NR}_x'-\text{N}$ -piperazine, where R_x is methyl, acetyl or preferably H.
23. **(Original)** A compound according to claim 1, wherein R1 is $-\text{NR}_x\text{R}_x$, $-\text{N}(\text{C}=\text{O})\text{C1-C4-alkyl}$ or $-\text{NHC}(=\text{O})\text{CH}_2\text{OC1-C3-alkyl-COOR}_x$.
24. **(Original)** A compound according to claim 23, wherein R1 is $-\text{NH}_2$, $-\text{NHC}(=\text{O})\text{Me}$ or $\text{NHC}(=\text{O})\text{CH}_2\text{OCH}_2\text{C}(=\text{O})\text{OH}$.
25. **(Original)** A compound according to claim 1, wherein R1 is $-\text{C1-C3-alkyl-COOR}_x$; $-\text{C1-C3alkyl-OR}_x$, $-(\text{O-C1-C3alkyl})_q\text{-O-R}_x$ or a 5 membered ring having 1-3 hetero atoms.
26. **(Original)** A compound according to claim 25, wherein R1 is carboxyethyl or a methyl ester thereof, 2-methoxyethoxyethoxy or triazolyl.
27. **(Original)** A compound according to claim 1, wherein R1 is para to the ether linkage.

28. **(Original)** A compound according to claim 1, wherein the ring containing A is phenyl or pyrid-3-yl.
29. **(Original)** A compound according to claim 1, wherein R2 is hydrogen or fluoro.
30. **(Original)** A compound according to claim 1 where R2 is meta to the ether linkage.
31. **(Currently amended)** A compound according to claim 1 denoted N-[(1S,1aR,7bR)-4,7-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-1-yl]-N'-[5-(4-(sulfonamido)phenoxy)-2-pyridinyl]urea



32. **(Original)** A pharmaceutical composition comprising a compound as defined in any preceding claim and a pharmaceutically acceptable vehicle or diluent therefor.
33. **(Original)** A composition according to claim 32, further comprising 1 to 3 additional HIV antivirals.

34. **(Original)** A composition according to claim 32, further comprising a cytochrome P450 modulator, such as ritonavir.
35. **(Previously Presented)** A method for the prophylaxis or treatment of HIV-1 infections comprising administering to an individual in need thereof an effective amount of the compound according to claim 1.
36. **(Previously Presented)** The method according to claim 35, wherein the HIV-1 infection is a drug escape mutant.
37. **(Previously Presented)** The method according to claim 36, wherein the drug escape mutant comprises the L100I and K103N mutations.
38. **(Currently Amended)** The method according to claim 35, wherein said compound is N-[(1S,1aR,7bR)-4,7-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-1-yl]-N'-[5-(4-(sulfonamido)phenoxy)-2-pyridinyl]urea



39. **(Previously presented)** The method according to claim 35, wherein the administration is vaginal.